Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement
Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 COLLABORATION AGREEMENT This Collaboration Agreement (this “ Agreement ”) is entered into as of June 9, 2026 (the “ Effective Date ”), by and between Vivos Therapeutics, Inc. , a Delaware corporation with principal offices at 7921 Southpa
How this was made
The 30-second read
Why it matters
This is a fresh corporate disclosure that may influence expectations for Vivos’ MSO footprint and operational complexity, particularly around healthcare regulatory compliance and referral-independence governance.
Market read
Material agreement entry plus defined MSO scope and ownership split can shift perceived execution and compliance risk for Vivos, though no financial terms are shown in the excerpt.
What to watch
The excerpt emphasizes referral independence and fair-market-value capitalization; traders should watch for the later Definitive Operating Agreement/MSAs for economics, timelines, and any compliance conditions that could delay commercialization.
Background
The 8-K discloses entry into a material definitive collaboration agreement to form AIM Florida, LLC, an MSO providing non-clinical administrative/technology/billing/payer contracting support for OSA diagnostic and treatment services in Florida.
Ticker impact
Vivos filed an 8-K for a material definitive collaboration agreement to form an MSO (AIM Florida, LLC) with SPCVA in Florida.
Likely modest, sentiment-neutral reaction unless investors view the MSO structure as materially expanding addressable OSA services or creating regulatory/operational risk.
The 8-K confirms entry into a material definitive agreement and outlines ownership (Vivos ≥80%) and MSO scope, but the excerpt provides no financial terms, guidance, or quantified impact.
Market effects
Highlights ongoing MSO/OSA care-delivery structuring and the need for compliance with Anti-Kickback/Stark/fee-splitting rules in sleep-disordered breathing care models.
Could increase competitive intensity for OSA diagnostic and treatment administration in Florida (Palm Beach County metro) via non-clinical MSO support.
Limited direct global read-across; more relevant to US healthcare services and MSO compliance frameworks.
Counterpoint
Investors may discount the deal if it is primarily administrative (MSO) with limited incremental clinical revenue, or if regulatory compliance constraints slow scaling.
Key entities
- issuerVivos Therapeutics, Inc.
Delaware medical technology company entering the collaboration agreement and expected to hold ≥80% of AIM Florida, LLC.
- counterpartySouth Palm Cardiovascular Associates, LLC
Florida cardiology practice collaborating with Vivos; expected to hold up to 20% of AIM Florida, LLC.
- new_entityAIM Florida, LLC
Florida limited liability company MSO intended to provide non-clinical support services to clinical entities delivering OSA care.
